A recent publication co-authored by core members of the EU-METAHEART COST Action focuses on the multifaceted mechanisms driving cardiac amyloidosis and explores potential therapeutic avenues. The paper, entitled “Mechanisms of Damage and Therapies for Cardiac Amyloidosis: A Role for Inflammation?”, emphasizes the role of inflammation in the progression of cardiac amyloidosis and its potential as a therapeutic target.
Cardiac amyloidosis, characterized by the accumulation of amyloid deposits in the heart, imposes unique challenges due to limited responsiveness to standard heart failure therapies. The review provides a comprehensive overview of the disease pathophysiology, prognostic markers, and emerging treatments, advocating for innovative strategies that target underlying mechanisms such as proteotoxicity, oxidative stress, and inflammatory pathways.
This work aligns with EU-METAHEART’s mission to foster interdisciplinary collaboration and advance our understanding of metabolic and cardiac diseases, paving the way for new interventions to improve patient outcomes.
For more information, read the full article here.
